Key Takeaways AMGN is set to report Q4 results on Feb. 3, with consensus calling for sales of $9.46B and EPS of$4.74.Amgen's newer drugs and biosimilars may lift sales, but Prolia and Xgeva face erosion after U.S. LOE.AMGN's prior-quarter one-time benefits won't be repeated, and higher R&D costs could weigh on margins.Amgen (AMGN) will report fourth-quarter and full-year 2025 results on Feb. 3 after market close. In the last reported quarter, the company's earnings beat expectations by 12.8%. The Zacks Con ...